logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
1/6/2022 8:33:31 AM Sangamo Reports Transition Of SAR445136 Sickle Cell Disease Program From Sanofi To Sangamo
12/12/2021 9:05:25 AM Sangamo Therapeutics Reports Updated Preliminary Proof-of-concept Data From Phase 1/2 PRECIZN-1 Study Of SAR44513
11/4/2021 9:14:20 AM Sangamo Therapeutics Q3 Attributable Loss $47.7 Mln Or $0.33/shr Vs. Loss $1.6 Mln Or $0.01/shr Prior Year
11/4/2021 8:17:26 AM Sangamo : Phase 1/2 Data Shows Tolerability And Sustained Elevated -Gal A Enzyme Activity In Patients With Fabry Disease
5/24/2021 4:28:34 PM Sangamo Therapeutics Appoints Prathyusha Duraibabu As CFO
12/7/2020 7:03:25 AM Pfizer, Sangamo Announce Updated Follow-up Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec
10/7/2020 6:50:00 AM Pfizer, Sangamo Dose First Participant In Phase 3 AFFINE Study Of Giroctocogene Fitelparvovec For Hemophilia A Patients
9/11/2020 8:35:00 AM Sangamo Therapeutics Appoints Kenneth Hillan To Board
6/24/2020 8:05:30 AM Sangamo Therapeutics Announces Changes To Its Research And Development Organization
6/18/2020 9:04:10 AM Pfizer, Sangamo Therapeutics Announce Updated Follow-up Data From Phase 1/2 Alta Study Of Giroctocogene Fitelparvovec
4/17/2020 8:36:44 AM Sangamo Therapeutics Appoints Mark McClung As EVP And Chief Business Officer
4/9/2020 8:05:06 AM Sangamo Therapeutics Announces Closing Of Previously Announced Sale Of Stock To Biogen